Summary of consensus practice points

  • The diagnosis and management of women with LCIS should involve a multidisciplinary team who consider all relevant pathological, radiological and clinical data, and the individual patient’s risk profile and preferences.
  • Patient involvement in the choice of management options is a key aspect of care. Women should receive adequate information regarding the implications of a diagnosis of LCIS, and the risks and benefits of the different management options.
  • Management options for the majority of women with LCIS include surveillance, surgical excision, and risk-reducing medication.
  • Surveillance includes annual clinical examination and bilateral imaging, subject to specialist clinical judgement (e.g. considering the age of the woman).
  • If LCIS of the classic variant is found in isolation or as an incidental finding (on core needle or excision biopsy), with pathological-radiological concordance, then surveillance remains an option.
  • If PLCIS is found on core needle biopsy, excision should be performed.
  • If other sub-types of LCIS (such as classic LCIS with comedo-type necrosis and florid/bulky LCIS) are found on core needle biopsy, excision may be considered.
  • There is no evidence to support the use of radiotherapy for LCIS in general, but adjuvant radiotherapy may be considered for women with PLCIS.
  • Risk-reducing medication, including aromatase inhibitors or selective oestrogen receptor modulators, is an option for preventing invasive breast cancer, subject to an individual woman’s overall clinical profile.